Bright Minds Biosciences Inc.
NCM: DRUGLive Quote
📈 ZcoreAI Score
Our AI model analyzes Bright Minds Biosciences Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get DRUG Z-Score →About Bright Minds Biosciences Inc.
Healthcare
Biotechnology
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
📊 Fundamental Analysis
Bright Minds Biosciences Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -27.0%, which indicates that capital utilization is currently under pressure.
At a current price of $83.55, DRUG currently sits at the 60th percentile of its 52-week range (Range: $23.18 - $123.75).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$817.72M
Trailing P/E
--
Forward P/E
-12.75
Beta (5Y)
-0.11
52W High
$123.75
52W Low
$23.18
Avg Volume
136K
Day High
Day Low